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management of congenital/genetic conditions. In the same
year only R112 million was spent on tuberculosis. Since
1983, these figures will have quadrupled owing to the effects
of inflation.
This study helped expedite the establishment of a clinical
genetics outreach programme in the area. It is hoped that
the information derived from the study will stimulate further
research in this field, and that it could be utilised for the
planning and provision of future family planning, genetic,
paediatric and prenatal services, and give impetus to the
initiation of specific programmes to reduce selected
common congenital anomalies such as Down syndrome,
NTDs and congenital hydrocephalus.
We thank Mrs Santie Swarts for her time and patience in
preparing the manuscript.
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G. D. Hussey, M. L. Lasser, w. D. Reekie
Haemophilus influenzae type b (Hib) infection is a major
cause of severe bacterial infection in young children in
South Africa and world-wide. These diseases can be
prevented by immunisation with conjugate Hib vaccines.
In South Africa, unlike some developed countries, Hib
vaccines are not part of the routine immunisation schedule.
The objective of this study was to measure the expected
net benefits from a hypothetical programme of vaccination
of the 1992 Cape Town birth cohort (N =46 537). Costs
were calculated by summing the estimated direct medical
care costs together with the indirect costs of Hib disease.
The latter were calculated by valuing human life using
alternative, and conservative human capital and
willingness-to-pay measures. The difference between Hib
disease costs (Le. the benefits which would be gained
from a successful vaccination programme) and the costs
of the vaccination programme itself (HibTITER, Praxis
Biologicals) defined the expected net benefits. In the
absence of an immunisation programme, the estimated
economic costs of Hib disease in the 1992 Cape Town
cohort ranged from R10,7 million to R11 ,8 million. The
costs of introducing the vaccine would have amounted to
R8,3 million. Had the vaccine been administered to the
1992 birth cohort, benefits would have exceeded costs by
between R2,4 million and R3,5 million.
S Atr Med J 1995; 85: 20-25.
Before the introduction of vaccination in developed
countries, invasive Haemophilus influenzae type b (Hib)
disease was one of the leading causes of severe, sometimes
fatal, bacterial disease in childhood.'.2 After vaccination was
introduced in the late 1980s3 the incidence of Hib disease
declined dramatically, and in some areas it has Virtually been
eliminated.'·5
A recent Cape Town study details the incidence, spectrum
and impact of Haemophilus influenzae (Hi) disease in South
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Africa." From 1 August 1991 to 31 July 1992, it is estimated
that there were 310 cases of invasive Hi disease (type band
non-type b); meningitis and pneumonia accounted for most
cases, while septicaemia, arthritis, mastoiditis and cellulitis
were also recorded. Ninety-eight per cent of cases occurred
in children aged under 5 years and 65% in children under
1 year. The mortality rates from meningitis, pneumonia and
septicaemia were 4,7%, 14,3% and 40%, respectively. Forty
per cent of meningitis patients had major complications on
admission to hospital and 17,6% continued to show
significant morbidity at discharge. Type b infection
accounted for 88% of cases."
In this paper, it will be assumed that the 1992 Cape Town
metropolitan birth cohort will be subject to a similar
cumulative disease pattern. Or, stated differently, the age
spread of Hib cases observed will be presumed to resemble
the expected disease course for the de facto unvaccinated
1992 cohort as it progresses to 5 years of age. Since the
1992 cohort is slightly larger than the four previous ones
which together with 1992 births led to the observed cases,
our assumed disease incidence rates may be slightly high.
However, given that the incidence peaks before 12 months,
this is a distortion of little consequence. Any exaggeration is
also offset by our exclusion of cases occurring after age 60
months. This assumption enabled us to calculate the
hypothetical net benefits of a vaccination programme
against Hib disease in 1992. We assume that the 1992 birth
cohort was 46 537-"" We calculated a cumulative 5-year
incidence for an annual birth cohort (the risk of disease over
a 5-year period) of 666 Hi cases per 100 000 births.
Hib infection can be prevented by immunisation. Since
most cases occur before the age of 1 year, the vaccine
should be administered soon after birth. The US Food and
Drug Administration (FDA) licensed the Lederle Laboratories
product HibTITER, a Hib oligosaccharide-diphtheria CRM,97
protein conjugate (HbOC), for use in infi'lnts from the age of
2 months. Vaccine efficacy is estimated to be 100% if 3
doses are administered.9When 2 doses are administered
efficacy is unaffected but the statistical confidence
decreases.. This paper compares the costs against the




The costs of Hib infection are the opportunity costs which
would have been avoided if HibTITER had been applied
retrospectively. These vaccine benefits (or opportunity costs)
were compared with the hypothetical costs of vaccination.
Net benefits are thus defined as the difference between the
costs with and without the proposed vaccine programme.
Disease costs include the indirect costs of illness relating to
death and disability as well as the direct costs of medical
treatment of and caring for patients with Hib disease.
Indirect costs require assessment of the value of individual
life and well-being. Direct costs necessitate analysis of Hib




Direct costs consist of personal medical care and non-
personal costs, such as research, prevention and testing.'·
The personal medical care costs of Hib disease were
concentrated on (non-personal costs either constitute a very
small fraction of total direct costs (e.g. prevention), or are
already sunk (e.g. research into the development of
vaccines), and so are amortised into the price of such
vaccines and therefore explicitly accounted for later in this
paper).
Indirect costs
Indirect costs embrace the value society places on death
and poor health resulting from Hib disease. Since morbidity
and mortality are not reflected through direct market
transactions, these costs must be assessed separately. The
three most common quantitative methods of estimating the
value of life (the benefits of avoided death) are the implied
value, the human capital, and the willingness-to-pay
approaches. The second approach and a conservative
variation of the third were adopted. The human capital
approach values life in terms of an individual's productive
output (equating output with earnings), discounted through
time and adjusted to allow for labour force participation. It
provides a floor evaluation since at least one objective of
health care is to return people to productive employment. If
there are other objectives, this floor must be a minimum."
The approach only captures a person's anticipated earnings
and ignores other measurements of his or her value to
family, friends and society. Furthermore, human capital
evaluation leads to relatively modest results in developing
countries such as South Africa because low average wages
and high unemployment result in reduced estimates in
relation to developed countries.
Willingness to pay overcomes these shortcomings by
estimating how much people would be willing to spend to
reduce their risk of death, regardless of their earning
capabilities.'2 This approach typically provides a higher
estimate of the value of life than either of the other methods.
In our variation of willingness to pay, we developed a
conservative 'hybrid' model which incorporated the floor
human capital method during employment years (18 - 65),
added to a willingness-to-pay component during non-
employment years (1 - 18; 65 - 100). In the non-
employment years, we conservatively used the minimum
subsistence expenditures as a measurement of willingness
to pay. Although Hib infection affects all income groups, in
our models we valued life conservatively by using earnings
and subsistence data only for the least well-off sector of
society. Any net benefits we computed can then be
regarded as minimum values, not likely or expected health
care savings.
Vaccine administration costs
Since it is proposed that the HbOC vaccine be administered
to infants concurrently with the diphtheria-tetanus-pertussis
(DTP) vaccine at 3, 4, 5 and 6 months of age, vaccine
administration costs would only involve the cost of the
vaccine, the incremental time required to vaccinate infants,
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Table 11. Mortality data for unvaccinated 1992 cohort
Disease Case fatality rate (%) No. of expected deaths
Discount rate and economic growth
We discounted model cost and benefit estimates through
time using an annual discount rate of 2% and assumed an
average annual real economic growth rate of 1% for the
economy.
that long-term morbidity would merely require monthly
outpatient visits for a 24-month period after initial discharge.
We estimated that meningitis patients suffering from
sequelae would require care costing approximately
R11 999,23 (R48 per outpatient visit x 24 months x 10,416
patients suffering sequelae).
We quantified the reduced labour productivity of patients
suffering from long-term morbidity in both the human capital
and willingness-to-pay approaches. We approximated the
average severity of sequelae on a 10-point scale from 0 to 1
(1 being death) at 0,1. That is, after 24 months of outpatient
care, we presumed that on average this small fraction of
patients is unable to work, still requires care, or is subject to
death. Since few data on distribution of the severity of
sequelae experienced by meningitis patients exist in South
Africa, we subjectively chose the most conservative
'sequelae index'. Next, we multiplied this by the number of
expected meningitis patients with sequelae (10,416) to
calculate 'long-term morality equivalents' at 1,04 (10,416"x
0,1). We added 1,04 to the total number of deaths expect~
in the 1992 cohort (26,625) to arrive at our 'total mortality
equivalent' figure of 27,665. Mortality estimates for the
unvaccinated 1992 population are summarised in Table 11.
The total mortality equivalent was employed in both models
to estimate the indirect costs of both morbidity and mortality















syringes, and vaccine side-effects. We assumed the joint
cost of a syringe and needle for HbOC vaccination to be
R1 ,50 per infant, implying administration costs of
R69 805,50 for the cohort. Although the time required to
vaccinate an infant is probably negligible (say an extra 60
seconds per infant, on 3 occasions), we proxied this by
including two nurses' salaries amounting to R72 466 in
administration costs. This may be an overestimate given that
DTP is administered simultaneously. If so, it again implies
that the net benefit figure will be downward-biased. Finally,
we assumed the price of a 3-vaccine dosage course at R175
per infant, or R8 143975 for the cohort. We estimated this
price from the 1988 US HbOC vaccine wholesale price of
US$14,13 adjusted it to 1992 dollars (using the medical care
weight within the Consumer Price Index), and then converted
to rands at the present exchange rate (US$1 = R3).
Vaccine efficacy and coverage
Although we assumed HbOC vaccine efficacy at 100%,
12% of Hi disease is non-type b (HibTITER will not prevent
Hi cases which are non-type b). Also, infants will only have
received the first 2 vaccine doses of a 3-dose course at the
age of 4'/2 months. For this reason, the raw data imply that
43 cases of Hi disease would still occur even if a vaccine
programme had been introduced. This figure includes cases
occurring after 4 and before 5 months of age. Some of these
cases would in fact have been prevented by a vaccine at 4,5
months. The exclusion of all 43 cases downward-biases our
results. We assumed 95% vaccine coverage (Le. 5% of
infants are not taken for vaccination by their mothers). In the
sensitivity analysis, the results were adjusted for coverage of
85% and 90%. The case data after excluding for the
vaccination schedule, non-type b cases, incomplete vaccine
coverage, and other factors are summarised in Table I.
Disease pattern without a vaccination
programme
Approximately 310 infants from the unvaccinated 1992
cohort will contract Hi disease. The clinical data indicate
that 24,2% would contract meningitis, 70% pneumonia,
2,9% ·septicaemia, and 2,9% other Hi disease.
Disease No.
Table I. Imperfect vaccine coverage and disease identity -
avoided disease spectrum estimate for the 1992 cohort
Mortality and morbidity
We defined morbidity as any health problems caused by the
Hib infection. Long-term morbidity includes neurological
sequelae or other physical or mental handicaps which
extend throughou a patient's life. The observed data
suggest that 17,6% of meningitis patients would suffer from
long-term morbidity. Although lifetime institutional care is











Lifetime earnings - human capital
approach
We adopted the average annual wage of the lowest income
section of society in our models. The Central Statistical
Office'· calculates the March 1992 national average monthly
wage rate for the RSA at R1 944, well above our annual
figure of R14 916. This latter figure is conservative for two
reasons. Firstly, it only relates to the most recently published
employment and salary data for the 1st quarter of 1992.,.
Given monetary inflation, the quarter 2 or 3 salary estimates
(which are presumably closer to the norm for the year) would
probably be higher than the quarter 1 data. Secondly, we
calculated the annual earnings using salary data for 'blacks',
the group with the lowest estimated average income. We
ignored average earrdngs data for the more highly .
renumerated 'whites, coloureds and Asians' categories. The
average salary and wage per month (in rands) for the non-
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Table Ill. Hospitalisation costs (R) for unvaccinated 1992 cohort
Meningitis Pneumonia Septicaemia Other
Other Hib disease costs
We identified, but did not quantify, other costs (which are
therefore vaccination benefits) associated with Hib disease.
For example, our models do not account for the foregone
earnings of parents caring for Hib-infected children, or for
the spread of Hib illness to others through contact with Hib-
infected infants. Our inability to quantify these costs further
L(c) =PAFACE years of survival to death given initial survival
to age 65 - 0,486.
We multiplied an individual's expected earnings/
subsistence costs by our total mortality equivalent to create
a second measure of the indirect costs of Hib disease
incurred by the 1992 cohort. In the subsistence/human
capital approach, we estimated a value of individual life of
R399892,17.
Hospitalisation costs
The Cape Town study led to the following hospitalisation
estimates for Hib disease: meningitis, 14,6 days; pneumonia,
10,9 days; septicaemia, 7,6 days; other Cape Town Hib
disease, 13,4 days. We assumed that hospitalisation in mid-
1992 would cost approximately R300 per day (to the extent
that this may be an underestimate, any net benefit we
compute will again be downward-biased). Table III shows
the expected avoidable hospitalisation costs for the 1992

















After consulting one US study which assessed the safety of
the Hib capsular polysaccharide vaccine, we estimated that
approximately 1 in 58 000 vaccinated infants would
experience severe side-effects due to vaccination against
Hib disease. We adopted this figure from a US study which
cited one anaphylactic reaction per 58 000 children
vaccinated against Hib infection." Treating such an
anaphylactic reaction would increase the direct vaccination
programme costs by approximately R3 600. We further
assumed that the mild febrile reaction associated with the
HbOC vaccine would lead to 1 out of 500 vaccinated infants
seeking medical attention." These medical visits would raise
the direct programme cost by approximately R13 402,65.
These estimates of the cost of vaccine side-effects are
conservatively high, since it is very unlikely that someone
who experiences side-effects will receive the full 3-dose
schedule. Furthermore, a study restricted to the HbOC
vaccine reported neither deaths nor hospitalisation
associated with the HbOC vaccine." Since we adopted the
much higher estimates of Hay and Oaum,13 who studied the
side-effects of a different conjugate vaccine, our model is
again not unconservative.
primary sectors of the RSA are as follows: total - 2 003;
whites - 3 543; coloureds - 1 489; Asians - 2 072; and
blacks - 1 243.'4 We assumed unemployment at 20% after
adjustment for informal sector activity.'5 The following
formula (see Appendix A for derivation) enabled us to
estimate the present value (in 1992) of the expected lifetime
earnings of an infant born in the 1992 cohort:
PV = [Y/(r-g)]*[(1 +g/1 +r)" - (1 +g/1 H)55j*L*e*(1 +g)"2,
where Y =annual wage rate (1992 prices) - R14 916;
r =discount rate - 0,02; g =growth rate - 0,01;
L = probability adjustment factor for actuarially computed
expected (PAFACE) years of survival to age 65 given initial
survival to age 17 - 0,94; PV =present value of an
individual's expected lifetime earnings; and e =probability of
employment - 0,8.
The term (1 + g)"2 explicitly introduces the assumption
that all births occur on the first of January and that all
income or earnings accrues to an individual during the
middle of the year. An individual's expected lifetime earnings
were multiplied by his probabilities of employment and
PAFACE years of survival to age 65 given the probability of
initial survival to age 17 (see Appendix A for explanation).
This yields an estimate of the value of life and hence failure
to survive to become an income-'generating member of the
population. It is the cost to society in foregone production of
an infant's death. We then multiplied this estimate by our
total mortality equivalent to calculate the expected indirect
costs of Hib diseases for the 1992 Cape Town birth cohort.
In this human capital approach, we calculated a floor value
of individual life at R359 267,85.
Subsistence/human capital approach
as a willingness-ta-pay proxy
We created a second model which combined a subsistence/
willingness-to-pay approach with the human capital method.
The subsistence model was used during an individual's non-
employment years (1 - 18 and 65 - 100) and the human
capital approach during employment years (18 - 65). In our
subsistence model, we assumed that the average annual
subsistence level during the lifetime of an Hib-infected
patient is R1 721. A previous study'" reported that the
September 1992 household subsistence level for a 6-person
'Iow-income' family in Cape Town was R860,50. We divided
. this by 6 and then multiplied the result by 12 to arrive at our
annual subsistence level of R1 271. The subsistence
approach conservatively assumes that minimum survival
costs are all that people would be willing to pay to remain
alive and in good health. The following formula was used in
this combination model (see Appendix A for derivation):
PV(c) = {[S/(r-g)]*[1- (1 +g/1 H)'"]*L(a)
+
e*[Y/(r-g)][(1 +g/1 H)" - (1 +g/1 H)55j*L(b)
[S/(r-g)]*[(1 +g/1 H)64 - (1 +g/1 H)"lO]*L(c)}*(1 +g)"2,
where PV(c) = present value of individual's expected lifetime
earnings/subsistence costs; S = annual subsistence level
(1992 prices) - R1 721; Y =annual wage rate (1992 prices)
- R14 916; r = discount rate - 0,02; g = growth rate -
0,01; e = probability of employment - 0,8; L(a) = PAFACE
years of survival to age 17 - 0,97; L(b) = PAFACE years of
survival to age 65 given initial survival to age 17 - 0,94; and
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Table V. Impac' .' value of life on model results (R cost
estimates)
stresses that our calculated net benefits of the vaccination
programme are significantly underestimated.
Results
A vaccine programme would have prevented direct and
indirect economic costs relating to 221,32 cases of Hib
disease. Our projected avoidable costs of Hib disease to
metropolitan Cape Town, including lost economic life,





































Table IV. Cost-benefit analysis in the human capital and
subsistence!human capital models (costs in R)
'Ufe value from human capital approach.































We also determined the sensitivity of results to parameter
assumptions by calculating different benefit/cost ratios
brought about by selected changes in important parameter
variables. Our alternative values for the discount rate and
expected economic growth rate had the largest impact on
results in both models (note that our maximum assumed
growth rate is 2,5% per annum contrasted with the
Education Renewal Strategy assumption of 3 - 4%; in short
we continue to choose conservative values). We summarise
the results of the sensitivity analysis in Table VI.
In the human capital model, we calculated total disease
costs (potential vaccine benefits) at R10 739 166,23, or
R230,77 per infant, using our base case assumptions.
Indirect costs contributed R9 939 145,00 to total
preventable disease costs and direct costs R800 021,23.
Had the 1992 Cape Town birth cohort been vaccinated, the
resulting total net benefits in our human capital model would
have been R2 435 917,07, or R52,34 per infant (after
deducting total vaccination administration costs of
R8 303 249,16 or R178,42 per infant).
The subsistence/human capital method as a willingness-
to-pay proxy led to higher preventable disease costs
(vaccine benefits) than the human capital model. Our
expected vaccination administration costs remained the
same in both models. We estimated that Hib disease costs
totalling R11 863 038,23 or R254,92 per infant, would have
been avoided if the 1992 cohort had been vaccinated.
Indirect costs amounted to R11 063 017 of total costs and
direct costs to R800 021,23. Net benefits would thus be
R3 559 789,07 and net benefits per infant R76,49. The
results of our two models using base case assumptions are
summarised in Table IV.
Sensitivity analysis
We performed sensitivity analysis to assess which base case
assumptions had the greatest impact on model results. The
effect of altering the value of life on our results is shown in
Table V. Since we calculated reasonable values of life in our
models (using the lowest average earnings data alone or in
combination with bare subsistence expenditure estimates), it
was helpful to recalculate model results using more realistic
values of life. Net benefits, savings per cohort member, and
benefit/cost ratios are shown for alternative life values in
Table V.
Table VI. Sensitivity of model net benefit/infant resulis to selected
changes in parameter values
Benefit! Benefit!
Base Alternative cost ratio cost ratio
Parameter value value(s) (HC) (SHe)
Base case 1,29 1,43
Discount rate (r) 0,02 0,015; 1,55; 1,72;
0,03 0,92 1,02
Growth rate (g) 0,01 0,025 2,27 2,52
Probability of 0,8 0,7; 1,14; 1,28;
employment (e) 0,9 1,44 1,58
Average annual 14916 13424,4 (-10%) 1,17; 1,31 ;
earnings (Y) 16407,6 (+10%) 1,41 1,55
Average annual 1 721 1548,9 (-10%) O· 1,42;
subsistence 1893,1 (+10%) 0 1,44
expenditure (S)
Vaccination 0,95 0,85; 1,02; 1,12;
coverage rate (V) 0,9 1,24 1,37
Vaccine price (R) 175 157,5 (-10%) 1,43; 1,58;
192,5 (+10%) 1,18 1,30
HC = benefit/cost ratio in human capital model; SHC= benefiUcost ratio in
subsistencelhuman capital model.
Discussion
Although we used the most conservative base values in
both the human capital and the subsistence/human capital
models, it is clear that the vaccination programme would
have produced net benefits arising from avoided disease
costs in metropolitan Cape Town ranging from
R2 435 917,07 to R3 559789,07. If we had been able to
quantify other disease costs, such as the spread of Hib
illness through contact with Hib infected infants or foregone
parental earnings, the net benefits estimates would have
been even higher.
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Given the difficulty of predicting future economic events
and the subjectivity inherent in attaching costs to morbidity
and mortality, we chose 'floor' base values in our models.
The promising results from our metropolitan Cape Town
study suggest the urgency of conducing further Hib disease
studies throughout South Africa.
Any net benefits would, of course, be much less in some
rural areas, where the value of life - as measured by the
utilitarian yardsticks of this study - would not only be less
but perhaps be meaninglessly so. For such areas we would
suggest that a more appropriate approach might be to
extend this study and use the concepts of disability-
adjusted life years and the related concept, the global
burden of disease. '• Public health policy makers would then
have to assess comparative disease burdens for Hib and
other diseases still not adequately provided for by primary
health care. Priority ranking would then be made by
comparing the annual rand cost per capita of alternative
strategies against forecasts of respective reductions in
disease burden to be obtained.
Nevertheless, infants could be vaccinated against Hib
. infection in conjunction with the DTP vaccination, and
significant net lifetime indirect and direct disease costs
could effectively be prevented, given our model's suggestion
that a national vaccination programme against Hib disease
could well produce substantial indirect and direct economic
savings.
This study was supported by grants from the Medical
Research Council and Lederle Laboratories.
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Our basic formula for the present value of an individual's
expected lifetime earnings between year k and year n is
equation 1:
PV = Y(1 +g)'"'/(1 +r)k+[Y(1 +g)k]/(1 +r)k.'+ ... [Y(1 +g)"-']1(1 +r)n,
where Y = annual wage rate; r = discount rate; and g =
growth rate.
We mUltiplied both sides of equation 1 by the term (1 +g)/
(1 +r) to arrive at equation 2:
PV[(1 +g)/(1 +r)] = [Y(1 +g)'/(1 +r)k.']+ ... +[Y(1 +g) =n]/(1 +r)n+l.
We then subtracted equation 2 from equation 1 to arrive
at equation 3:
PV-PV[(1 +g)/(1 +r)] = Y(1 +g)k·'/(1 +r)k_ {[Y(1 +g)n]/(1 +r)n+l}.
After simplifying equation 3, we arrive at equation 4:
PV = [Y/(r- g)]*[(1 +g)/(1 +r)]k.'] - [(1 +g)/(1 +r)]n
Equation 4 is employed in the human capital, subsistence
(substitution S = annual subsistence level for Y = annual
wage rate), and subsistence/human capital models.
The term L, the probability adjustment for actuarially
computed expected (PAFACE) years of survival to age n
given initial survival to age k, was arrived at through
obtaining two key actuarial statistics: P = the probability of
living to year n given that a person was alive until an earlier
year k; and E = the expected age of death given death
varies under n and over k.
We used life expectancy data from English Life Tables
Number 12, Life Contingencies, by Allister Neil!. Although
English actuaries generally estimate the terminal age at
between 103 and 105 years, we adopt 100 years as an
adequate approximation for South Africa. Our estimate is
more conservative given that South African blacks have a
lower life expectancy than English whites. The basic
equation for L used in the human capital, subsistence, and
subsistence/human capital approaches is:
L = P + [(E - k)/(n - k)](1 - P).
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